Akari Therapeutics (AKTX) Other financing activities (2015 - 2025)
Akari Therapeutics recorded quarterly Other financing activities of $33000.0 in Q2 2025, up 266.67% quarter-over-quarter from $9000.0 in Q4 2024, and up 375.0% year-over-year from $6947.4 in Q2 2024.
Akari Therapeutics' Other financing activities history runs 3 years deep, the most recent figure standing at $33000.0 for Q2 2025.
- In Q2 2025, Other financing activities rose 375.0% year-over-year to $33000.0; the TTM figure through Jun 2025 stood at $223000.0 (down 97.94% YoY), while the FY2024 annual figure was $193000.0, changed N/A from the prior year.
- Other financing activities came in at $33000.0 for Q2 2025 at Akari Therapeutics, up from $9000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $193000.0 in Q3 2024 to a low of -$12000.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 33,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | 193,000.00 |
| Sep 30, 2024 | 193,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Jun 30, 2024 | 12,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2015 | 10.84 Mn |
| Dec 31, 2015 | 10.84 Mn |